Loading...

Natera, Inc.

NTRANASDAQ
Healthcare
Medical - Diagnostics & Research
$159.81
$2.77(1.76%)

Natera, Inc. (NTRA) Financial Performance & Income Statement Overview

Explore the financials of Natera, Inc. (NTRA), including yearly and quarterly data on income, cash flow, and balance sheets.

Revenue Growth
56.75%
56.75%
Operating Income Growth
50.19%
50.19%
Net Income Growth
56.20%
56.20%
Operating Cash Flow Growth
154.93%
154.93%
Operating Margin
-14.95%
14.95%
Gross Margin
62.91%
62.91%
Net Profit Margin
-12.89%
12.89%
ROE
-22.21%
22.21%
ROIC
-21.40%
21.40%

Natera, Inc. (NTRA) Income Statement & Financial Overview

Access detailed annual and quarterly income data for Natera, Inc. NTRA financial performance.

MetricQ1 2025Q4 2024Q3 2024Q2 2024
Revenue$501.83M$476.06M$439.76M$413.35M
Cost of Revenue$184.61M$176.42M$168.01M$170.18M
Gross Profit$317.22M$299.64M$271.75M$243.17M
Gross Profit Ratio$0.63$0.63$0.62$0.59
R&D Expenses$129.08M$129.46M$96.93M$89.11M
SG&A Expenses$266.86M$234.92M$214.15M$197.97M
Operating Expenses$396.39M$364.38M$311.08M$287.07M
Total Costs & Expenses$581.007M$540.80M$479.10M$457.25M
Interest Income$13.42M$10.91M$11.62M$10.46M
Interest Expense$1.005M$1.29M$3.14M$3.13M
Depreciation & Amortization$9.24M$7.79M$8.20M$7.92M
EBITDA-$56.52M-$46.04M-$19.52M-$25.53M
EBITDA Ratio-$0.11-$0.10-$0.04-$0.06
Operating Income-$79.18M-$64.74M-$39.34M-$43.90M
Operating Income Ratio-$0.16-$0.14-$0.09-$0.11
Other Income/Expenses (Net)$12.41M$9.61M$8.48M$7.33M
Income Before Tax-$66.76M-$55.13M-$30.86M-$36.57M
Income Before Tax Ratio-$0.13-$0.12-$0.07-$0.09
Income Tax Expense$173000.00-$1.35M$730000.00$892000.00
Net Income-$66.94M-$53.77M-$31.59M-$37.46M
Net Income Ratio-$0.13-$0.11-$0.07-$0.09
EPS-$0.50-$0.41-$0.26-$0.30
Diluted EPS-$0.50-$0.41-$0.26-$0.30
Weighted Avg Shares Outstanding$134.75M$124.72M$123.78M$122.85M
Weighted Avg Shares Outstanding (Diluted)$134.75M$124.72M$123.78M$122.85M

Over the last four quarters, Natera, Inc. achieved steady financial progress, growing revenue from $413.35M in Q2 2024 to $501.83M in Q1 2025. Gross profit stayed firm with margins at 63% in Q1 2025 versus 59% in Q2 2024. Operating income totaled -$79.18M in Q1 2025, maintaining a -16% margin over recent quarters. Despite shifts in R&D and SG&A costs, EBITDA stayed strong at -$56.52M. Net income dropped to -$66.94M, with EPS at -$0.50. Disciplined expense strategies and efficient operations ensured sustained profitability and long-term financial stability.

Unlock 25+ Years of Financial Data

Get access to extended historical data, advanced metrics, and more with our premium plan

Frequently Asked Questions

;